TOP > 外国特許検索 > PEPTIDE-BOUND LIPOSOME, CYTOTOXIC T LYMPHOCYTE ACTIVATOR, AND ANTITUMOR VACCINE

PEPTIDE-BOUND LIPOSOME, CYTOTOXIC T LYMPHOCYTE ACTIVATOR, AND ANTITUMOR VACCINE

外国特許コード F160008807
整理番号 (S2014-1594-N0)
掲載日 2016年8月4日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP076214
国際公開番号 WO 2016047509
国際出願日 平成27年9月16日(2015.9.16)
国際公開日 平成28年3月31日(2016.3.31)
優先権データ
  • 特願2014-196454 (2014.9.26) JP
発明の名称 (英語) PEPTIDE-BOUND LIPOSOME, CYTOTOXIC T LYMPHOCYTE ACTIVATOR, AND ANTITUMOR VACCINE
発明の概要(英語) A peptide-bound liposome wherein a peptide comprising the amino acid sequence represented by SEQ ID NO:14 is bound to the surface of a liposome.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, T lymphocytes are cytotoxic to a tumor antigen (hereinafter, sometimes referred to as' CTL ') inducing a reaction, the activated CTL is expected to be in the tumor cells may be eliminated immune therapy are under research and development has been actively carried out. The immunotherapy includes, tumor antigen peptides of the vaccine-induced CTL developed with the center.
So far, Telomere Reverse Transcriptase (hereinafter, sometimes referred to as' TERT ') a tumor antigen peptide is a target antigen has been proposed (for example, see Patent Document 1 and 2). The TERT is, various types of clinical tumor expression is observed in a time sharing about 9 pan-tumor antigen. Therefore, cause a strong immune response against the antigen derived from TERT vaccine, which is highly versatile and universal anti-tumor vaccine that can be expected.
In general, search for candidate vaccine antigen epitope, the amino acid sequence of antigenic proteins may be analyzed by a computer algorithm, the expectation that high affinity HLA material should be selected in many cases (for example, see non-patent document 1). The TERT in using peptide vaccine-derived antigens, peptide antigens currently in clinical trials is 540-548, the native sequence of the TERT in the prediction for the highest affinity HLA-A2 sequence (for example, see non-patent document 2).
However, so far fully satisfactory in the anti-tumor vaccine is not provided. This is, detected from the peripheral blood of patients with tumor tumor antigen-specific cytotoxic T lymphocytes, react to antigen stimulation entereds be considered that the reason. This is caused, neoplastic growth in the course of, and has a high affinity HLA, to the host immune system can be easily identified from tumor cells presented CTL epitope, it is considered that immune tolerance is induced. In addition, the tumor antigen peptide, MHC class I receptor also coupled for, inappropriate co-stimulation in the form lacking the antigen-presenting cells and thus T, administered antigen specific immune tolerance can cause also contemplated.
Therefore, the self antigen is derived from the protein at high affinity epitope TERT, neoplastic growth T lymphocytes from the tumor cells to the antigen in the course presented, as a result, a problem that the immune tolerance is induced may be considered. Antigen-specific immune tolerance is induced in the case, antigen-specific T lymphocytes non-responsive state and to the activation stimulus, sufficient anti-tumor effect and cytotoxic T lymphocytes induced by anti-tumor vaccine is expected to be difficult.
On the other hand, so far, the surface of the liposomes composed of unsaturated fatty acids may be coupled with an antigenic peptide, a professional antigen presenting cell (hereinafter, sometimes referred to as' pAPC ') incorporated in the specific, MHC class I cross-presentation to the, co-stimulation with antigen presented in a form suitable for known (for example, see non-patent document 3).
However, without inducing immune tolerance, which can cause a cellular immune response, anti-tumor vaccine has not been developed yet, it is strongly demanded to provide a rapid.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAITAMA MEDICAL UNIVERSITY
  • 発明者(英語)
  • HORIUCHI, Yutaka
  • AKATSUKA, Toshitaka
  • UCHIDA, Tetsuya
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close